ReviewNature reviews. Immunology2017
The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting.
Review in Nature reviews. Immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04486027 (Can Cytokines be Used as an Activation Marker in Rheumatoid Arthritis), which is not on this map. Cited by 231 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Can Cytokines be Used as an Activation Marker in Rheumatoid Arthritis
Who cites it
231 citing papers in PubMed, 5 syntheses or guidelines pooled it, 436 citations in OpenAlex.
- Exposure to Occupational Inhalants and the Risk of Developing Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Pooled it
- Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.Annals of the rheumatic diseases · 2024Pooled it
- Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.Frontiers in immunology · 2022Pooled it
- Fc Gamma Receptors as Regulators of Bone Destruction in Inflammatory Arthritis.Frontiers in immunology · 2021Pooled it
- A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis.Scientific reports · 2020Pooled it
- The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.Arthritis research & therapy · 2021Trial
- Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.Annals of the rheumatic diseases · 2021Trial
- Exploring inflammatory signatures in arthritic joint biopsies with Spatial Transcriptomics.Scientific reports · 2019Trial
- CD27 Neutralization Attenuates Rheumatoid Arthritis by Suppressing.Biochemical genetics · 2026Article
- Specificity, frequency, and phenotype of citrullinated-specific T cells vary with disease activity in rheumatoid arthritis.JCI insight · 2026Article
- Long-Term Outcomes in Seronegative Rheumatoid Arthritis.Arthritis care & research · 2026Article
- Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis.RMD open · 2026Article
- Capturing multi-disease states on a spectrum with machine learning and routine clinical data.Med (New York, N.Y.) · 2026Article
- Cross-presentation of citrullinated antigens drives cytotoxic CD8bioRxiv : the preprint server for biology · 2026Article
- Preclinical Rheumatoid Arthritis: Pathogenesis, Risk Stratification, and Therapeutic Interception.Journal of clinical medicine · 2026Review
- Bavachin suppresses NF-κB signaling and angiogenic pathways to alleviate rheumatoid arthritis.Archives of pharmacal research · 2026Article
- Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.International journal of molecular sciences · 2026Review
- First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.Journal of comparative effectiveness research · 2026Article
- Impact of the 2018 Japan Floods on Methotrexate and Antirheumatic Drug Prescriptions: A Longitudinal Analysis of the Japanese National Database.JMA journal · 2026Review
171 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with rheumatoid arthritis can be divided into two major subsets characterized by the presence versus absence of antibodies to citrullinated protein antigens (ACPAs) and of rheumatoid factor (RF). The antibody-positive subset of disease, also known as seropositive rheumatoid arthritis, constitutes approximately two-thirds of all cases of rheumatoid arthritis and generally has a more severe disease course. ACPAs and RF are often present in the blood long before any signs of joint inflammation, which suggests that the triggering of autoimmunity may occur at sites other than the joints (for example, in the lung). This Review summarizes recent progress in our understanding of this gradual disease development in seropositive patients. We also emphasize the implications of this new understanding for the development of preventive and therapeutic strategies. Similar temporal and spatial separation of immune triggering and clinical manifestations, with novel opportunities for early intervention, may also occur in other immune-mediated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.